Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery.

Literature DB >> 30249689

Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery.

Emma Padilla¹, Lluis Oms², Elena Espejo³, Laura Gómez², Lurdes Pagespetit⁴, Núria Boada⁴, Feliu Bella³, Josefa Pérez⁵.

Abstract

The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.

Entities: Chemical Species

Keywords: Staphylococcuszzm321990; antibiotic resistance; rifampin; rifaximin; surgical prophylaxis

Mesh：

Substances：

Year: 2018 PMID： 30249689 PMCID： PMC6256800 DOI： 10.1128/AAC.01353-18

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.

Authors: Thomas Valentin; Eva Leitner; Angelika Rohn; Ines Zollner-Schwetz; Martin Hoenigl; Helmut J F Salzer; Robert Krause
Journal: J Infect Date: 2010-11-10 Impact factor: 6.072

2. Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin.

Authors: Paul O Lewis; Imran Khan; Paras Patel
Journal: Ann Pharmacother Date: 2017-03-20 Impact factor: 3.154

3. Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin.

Authors: Thomas Valentin; Martin Hoenigl; Jasmin Wagner; Robert Krause; Ines Zollner-Schwetz
Journal: J Infect Date: 2014-04-26 Impact factor: 6.072

Review 4. Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns.

Authors: Audrey Tupin; Maxime Gualtieri; Françoise Roquet-Banères; Zakia Morichaud; Konstantin Brodolin; Jean-Paul Leonetti
Journal: Int J Antimicrob Agents Date: 2010-02-24 Impact factor: 5.283

5. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin.

Authors: M Drancourt; A Stein; J N Argenson; R Roiron; P Groulier; D Raoult
Journal: J Antimicrob Chemother Date: 1997-02 Impact factor: 5.790

6. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.

Authors: Javier A Adachi; Herbert L DuPont
Journal: Clin Infect Dis Date: 2006-01-17 Impact factor: 9.079

Review 7. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors: J C Gillis; R N Brogden
Journal: Drugs Date: 1995-03 Impact factor: 9.546

8. Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.

Authors: Herbert L DuPont; Ray A Wolf; Robert J Israel; Mark Pimentel
Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191

9. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Authors: M Pimentel; B D Cash; A Lembo; R A Wolf; R J Israel; P Schoenfeld
Journal: Dig Dis Sci Date: 2017-06-06 Impact factor: 3.199